Related Experiment Video
Updated: Jun 17, 2026
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Lung ultrasound (LUS) and surfactant treatment: looking for the best predictive moment
Gozdem Kayki1, Sule Yigit2, Umit Ayse Tandircioglu2
1Division of Neonatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey. gozdemkayki@hotmail.com.
Objective:
Assess the earliest time of LUS to guide surfactant therapy.
Study Design:
In this observational study (ClinicalTrials.gov Identifier NCT04544514), LUS was performed within 30 min and repeated at 1, 2, 4, and 6 h on preterm babies. White lung appearance was defined as type 1 group, whereas prevalence of lines B as type 2 and lines A as type 3. Ultrasound and radiographic findings were also compared to determine surfactant need.
Results:
Among 71 patients, 41 received surfactant therapy. In the first evaluation, 37 of them have been defined as type 1, whereas 4 of them have been as type 2 group. Type 3 group did not receive surfactant. Type 1 findings were superior to predict surfactant need and the predictive value was 100% at 2 h.
Conclusion:
Even early LUS assessment at the first 20-30 min was more significant to predict surfactant need than x-ray. Presence of white lung appearance for 2 h indicates an absolute surfactant need.
